Intermittent Eating on Sustaining Weight-loss in Obesity
INTEREST
Effects of Intermitting Eating on Weight-Loss Maintenance and Cardiometabolic Risk Factors in Obese Adults: A Randomized Clinical Trial
1 other identifier
interventional
270
1 country
1
Brief Summary
Weight regain after weight loss is a major problem in the treatment of obesity. Two novel types of intermittent fasting recently have received more attention: the 5:2 diet and time-restricted eating (TRE). TRE requires individuals to eat in a specified number of hours per day (typically 4 to 10 hours) without energy intake restriction. The 5:2 diet involves 5 feast days and 2 fast days per week; participants eat ad libitum without restriction on feast days while 25% of energy needs (approximately 500-800 kcal per day) are consumed on fast day. This randomized controlled trial aimed to evaluate the effect of TRE and the 5:2 diet on weight loss maintenance and cardiometabolic risk factors after a low-calorie diet in obese adults over 12 months compared to usual health care.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable obesity
Started Oct 2022
Typical duration for not_applicable obesity
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 18, 2022
CompletedFirst Posted
Study publicly available on registry
July 12, 2022
CompletedStudy Start
First participant enrolled
October 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 15, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
July 15, 2025
CompletedNovember 9, 2023
November 1, 2023
2.8 years
June 18, 2022
November 8, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in body weight over 12 months
Baseline to months 12
Secondary Outcomes (16)
Change in body fat composition meassured by DEXA
Baseline to months 12
Change in waist circumference
Baseline to months 12
Change in body mass index
Baseline to months 12
Change in liver fat
Baseline to months 12
Change in systolic blood pressure
Baseline to months 12
- +11 more secondary outcomes
Study Arms (3)
The TRE group
EXPERIMENTALParticipants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm).
The 5:2 diet group
EXPERIMENTALParticipants in the 5:2 diet group will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
Control
NO INTERVENTIONParticipants in the control group will receive a general lifestyle counseling.
Interventions
Participants in the TRE group will be instructed to eat during a window of 8 h/d (8 am to 4 pm)
Participants will be instructed to consume 500-600 kcal/d on fast days and eat ad libitum on feast days.
Eligibility Criteria
You may qualify if:
- Man or women aged 18-75 years;
- Body mass index (BMI)of 28.0 to 45.0 kg/m2;
You may not qualify if:
- \. History of HIV, hepatitis B or C (self-report) or active pulmonary tuberculosis;
- \. Diagnosis of type 1 and type 2 diabetes;
- \. History of malignant tumors;
- \. Serious liver dysfunction or chronic kidney disease (AST or ALT \> 3 times the upper limit of normal, or eGFR\<30 ml/min/1.73 m2);
- \. History of serious cardiovascular or cerebrovascular disease (angina, myocardial infarction or stroke) in the past 6 months;
- \. History of severe gastrointestinal diseases or gastrointestinal surgery in the past 12 months;
- \. History of Cushing's syndrome, hypothyroidism, acromegaly, hypothalamic obesity;
- \. Being a smoker or having been a smoker in the 3 months prior to their screening visit;
- \. Taking medications affecting weight or energy intake/energy expenditure in the last 6 months, including weight loss medications, antipsychotic drugs or other medications as determined by the study physician;
- \. Currently participating in weight loss programs or weight change in the past 3 months (\> 5% current body weight) ;
- \. Women who are pregnant or plan to become pregnant;
- \. Patients who cannot be followed for 24 months (due to a health situation or migration);
- \. Patients who are unwilling or unable to give informed consent.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, 510515, China
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Huijie Zhang, MD. PhD.
Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
June 18, 2022
First Posted
July 12, 2022
Study Start
October 1, 2022
Primary Completion
July 15, 2025
Study Completion
July 15, 2025
Last Updated
November 9, 2023
Record last verified: 2023-11
Data Sharing
- IPD Sharing
- Will not share